Neoleukin was benched by the FDA with a clinical hold for the biopharma company’s lead cancer immunotherapy candidate.
Five key genes are linked with the most severe form of Covid-19, scientists said, in research that also pointed to several existing drugs that could be repurposed to treat people who risk getting critically ill with the pandemic disease.
As Death Toll Climbs, WHO Finds No Benefit with 4 Top Covid-19 Treatments
Antiretrovirals, Biopharma Companies, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Hospitalized COVID-19 Patients, Hydroxychloroquine, Interferon-beta-1a, Lopinavir, Mortality Rates, New England Journal of Medicine, R&D, Remdesivir, World Health OrganizationOnce touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.
WHO study says remdesivir did not cut hospital stay or mortality in Covid-19 patients
Antivirals, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Covid-19 Data, Hospitalized COVID-19 Patients, Hydroxychloroquine, Immunomodulator Drugs, Monoclonal Antibodies, Mortality, R&D, Remdesivir, World Health OrganizationGilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
A year after Bristol-Myers Squibb walked away from acquiring Promedior and the company’s fibrotic treatment portfolio, Roche stepped in to acquire the biotech firm for up to $1.4 billion.
Shares of Karyopharm Therapeutics skyrocketed more than 36 percent after the U.S. Food and Drug Administration approved the Newton, Mass.-based company’s Xpovio for treating multiple myeloma.
Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate
Analysts, Analytics, Approvals, August 2018, Biologics, Biosimilars, Blockbusters, Business, Cannabinoids, Dravet syndrome, Epilepsy, EvaluatePharma, FDA/Regulatory, Gastroenterology, GlobalData, Immunological Disorders, Immunology, Immunomodulator Drugs, Innovation, Issue Archives, Lennox-Gastaut Syndrome (LGS), Mantle Cell Lymphoma (MCL), Myelodysplastic Syndromes, Prostate Cancer, Shingles, Special Reports, Therapeutics, Top 200 Medicines, Tumor Necrosis Factor (TNF) Inhibitors, Ulcerative ColitisThere were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.